NCT06779695Active, not recruiting
Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)
Source: ClinicalTrials.gov · Last updated 16 Jan 2025
Brief summary (registry, in English)
Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 13 Jan 2025
- Start date
- 21 Apr 2024
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Korea University Anam Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT06779695
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 21 Apr 2024 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of clinically significant alcohol or drug abuse.
Lab values
- Patients with creatinine clearance (CCr) less than 15 ml/min.
Other
- Patients with moderate to severe mitral stenosis.
- Patients who have undergone mechanical valve replacement
- Patients whom the investigator deems legally or mentally unsuitable for participation in the clinical trial, or those who do not consent to participate in the study.
Who the study is looking for
- Male and female patients aged 19 years or older with chronic atrial fibrillation, accompanied by at least one of the following conditions:
- ① Heart failure
- ② 2. Myocardial infarction (more than 3 months post-event)
- ③ 3. Angina (if PCI was performed, more than 3 months post-procedure)
- ④ 4. Hypertension
- ⑤ 5. Diabetes mellitus
- Patients who started taking Factor Xa inhibitors (Apixaban, Rivaroxaban) within the last 12 months and have echocardiographic images taken within 3 months of that time, which are available for analysis.
- Patients who are starting treatment with Factor Xa inhibitors. (Apixaban, Rivaroxaban)
- Individuals who have voluntarily provided written consent to participate in this clinical trial.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Korea University Anam Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.